PRINCETON, N.J. & OSAKA, Japan--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE:BMY) and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; "Ono") announced an agreement that grants Bristol-Myers Squibb an exclusive license for the development and commercialization of ONO-4578, Ono's selective Prostaglandin E 2 (PGE 2 ) receptor 4 (EP 4 ) antagonist. The companies will also collaborate on discovery efforts to identify additional compounds from Ono's PGE 2 receptor antagonist programs.